Mounjaro and Anaesthesia Guidelines: What You Need to Tell Your Surgical Team

The misconception worth clearing up first: 'It's only a weight-loss injection, so it probably doesn't matter for surgery'

This is the most common misunderstanding our prescribers hear on this topic, sometimes from patients who have already had pre-operative conversations and did not think to mention Mounjaro. The assumption is that a once-weekly subcutaneous injection sits outside the usual list of medicines to declare. It does not. Tirzepatide acts on both GIP and GLP-1 receptors in ways that affect the whole gut, not just appetite. One of its most clinically significant effects is a substantial reduction in the rate at which the stomach empties. For most people, most of the time, that slower transit is part of how the medicine works. In the context of surgery, it creates a separate problem: stomach contents that would normally have cleared during a standard fasting window may not have done so. If a patient vomits or regurgitates during induction of anaesthesia, those contents can reach the lungs, a complication called pulmonary aspiration, which can be serious. The risk is not theoretical. It has been reported in anaesthetic and surgical literature, and it is precisely why both NHS England and the professional anaesthetic bodies have issued formal guidance. Declaring Mounjaro before surgery is not a bureaucratic formality; it lets the anaesthetic team adapt their approach before they begin, not after a problem arises. If you have a procedure scheduled and are currently taking Mounjaro, the conversation with your surgeon and anaesthetist should happen at your pre-assessment appointment, as early as possible.

What the clinical guidance actually says, and who it comes from

NHS England's guidance on weight-management injections states plainly that patients should tell their healthcare team, including their anaesthetist, that they are taking a GLP-1 or dual-agonist medicine before any surgical procedure. This applies to tirzepatide (Mounjaro) and to semaglutide (Wegovy). The Royal College of Anaesthetists and the Association of Anaesthetists have both addressed this in their own communications, reflecting a genuine shift in pre-operative assessment practice. The central practical questions your anaesthetic team will consider are: how recently you took your last dose; whether additional precautions around fasting are warranted; and whether the type of airway management should be adjusted. Some teams request a longer fasting period than the standard guidance. Others consider using a technique that protects the airway during induction more aggressively. Some services ask whether it is clinically appropriate for a patient to pause tirzepatide in the week before an elective procedure, though this is not a blanket recommendation, and it depends entirely on your individual circumstances, the nature of the operation, and your prescriber's view. The detail of what applies to general anaesthetic procedures specifically differs from considerations for shorter sedation-based procedures, and the picture for local anaesthetic use is different again. Gastric emptying slows on tirzepatide regardless of the route of anaesthesia, but the aspiration risk is most relevant when protective airway reflexes are reduced, which is primarily under general anaesthetic or deep sedation. This is also one reason why dental anaesthetic contexts warrant a separate look: most routine dental work uses local anaesthetic only, and the risk calculus changes accordingly.

Should you stop Mounjaro before surgery, and if so, when?

There is no single universal answer, which is itself worth stating clearly. Guidance from NHS England and anaesthetic bodies does not specify a fixed hold period that applies to every patient in every situation. The decision involves weighing the aspiration risk against the clinical value of continued treatment, the type and urgency of the procedure, and whether pausing will disrupt a carefully titrated treatment plan. Tirzepatide has a long half-life, effects on gastric motility do not disappear the morning after you skip a dose. Some elective surgical services have begun asking patients to omit the dose in the week before a planned procedure; others work with an extended fasting protocol instead. Neither approach overrides the need for a direct conversation between your prescriber, your surgical team, and you. What you should not do is quietly skip doses on the assumption that it resolves the issue, or continue without telling anyone on the assumption that it does not matter. Both carry risk. If you are unsure what to do, contact whoever prescribed your Mounjaro, they can liaise with your surgical team and reach a plan that accounts for your whole clinical picture. You can also read the broader guidance on Mounjaro and anaesthesia for more context on how these conversations typically unfold. For background on how tirzepatide works as a medicine, the NHS tirzepatide page covers its mechanism and known effects in accessible terms. The licensed uses of tirzepatide in the UK are also worth understanding if questions come up during pre-operative assessment about why you are taking it.

Starting or continuing Mounjaro around a surgical procedure

People who are partway through treatment sometimes ask whether surgery means they should stop Mounjaro altogether, or whether they can restart straightaway once they recover. Again, this is a clinical decision. If treatment is paused around a procedure, restarting involves the same clinical review as any dose change. It is not a case of simply picking up where you left off, particularly if the pause extends beyond a short period. There is also a separate question for people who are considering starting Mounjaro but have surgery planned in the near future: it is worth raising the timing at your consultation, so that your prescriber can factor it in from the outset. Tirzepatide is one of the options available for weight management in the UK, and the suitability assessment already considers your full medical history, an upcoming procedure is part of that picture. If cost context is relevant to your decision-making, the background on Eli Lilly's UK pricing changes may be useful reading. And if you want to understand how our clinical team approaches these kinds of decisions, our clinical lead's profile gives a sense of the oversight behind every consultation at nume.